|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to assess the efficacy and safety of bicalutamide plus another aromatase inhibitor in patients with nonsteroidal aromatase inhibitor (AI) or steroidal AI resistance and estrogen receptor (ER)-positive and AR-positive advanced breast cancer.
|
31434793 |
2020 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
|
30361875 |
2019 |
|
Advanced breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
|
30941621 |
2019 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Expert opinion</b>: While fulvestrant has limited use in the first-line setting in advanced breast cancer, it is most frequently used in the second line after progression with aromatase inhibitors.
|
31486688 |
2019 |
|
Advanced breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The goal of this review is to estimate the effect of Aromatase Inhibitors (AIs), Tamoxifen (TAM) and Fulvestrant (FUL) on the development of ESR1 mutations in hormone-sensitive advanced breast cancer.
|
31647985 |
2019 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Letrozole is an aromatase inhibitor, used to treat postmenopausal women with hormone receptor-positive or unknown advanced breast cancer.
|
30506949 |
2019 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination therapy with a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor and an aromatase inhibitor (AI) for first-line treatment of postmenopausal women with advanced breast cancer (ABC) has demonstrated improvement in progression-free survival (PFS) over AI monotherapy without adding substantial toxicity.
|
30655702 |
2019 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fulvestrant is recommended for patients with hormone receptor-positive (HR+) advanced breast cancer (ABC) who progress after aromatase inhibitor therapy.
|
30136059 |
2019 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
|
30563991 |
2019 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (palbociclib and abemaciclib) and mammalian target of rapamycin (mTOR) inhibitors (everolimus) are effective agents for restoring endocrine sensitivity in patients with advanced breast cancer progression on prior aromatase inhibitors.
|
30608416 |
2019 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we describe the design and methodology of EMERALD, an international, multicenter, randomized, open-label, active-controlled, Phase III clinical study comparing the efficacy and safety of elacestrant to standard-of-care endocrine monotherapy treatment (fulvestrant or an aromatase inhibitor, per investigator's choice) in patients with ER-positive/HER2-negative advanced breast cancer.
|
31426673 |
2019 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
ESR1 mutations are rare in primary breast cancer but have high prevalence in patients treated with aromatase inhibitors (AI) for advanced breast cancer.
|
29045530 |
2018 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Open-label, randomized, phase 2 trial of treatment effects in postmenopausal women with advanced breast cancer that had progressed during treatment with nonsteroidal aromatase inhibitors.
|
29862411 |
2018 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This meta-analysis was conducted to compare the efficacy and safety of fulvestrant with aromatase inhibitors in postmenopausal women with hormone receptor-positive (estrogen and/or progesterone receptor positive) advanced breast cancer.
|
29974356 |
2018 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer.
|
29190006 |
2018 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ribociclib is an orally bioavailable cyclin-dependent kinase (CDK) 4/6 inhibitor that has been approved for use in combination with an aromatase inhibitor for the treatment of HR<sup>+</sup>, human epidermal growth factor receptor 2-negative (HER2<sup>-</sup>) advanced breast cancer.
|
30340505 |
2018 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fulvestrant is a selective oestrogen receptor downregulator (SERD) which was introduced to clinical practice in 2002, initially with the indication to treat postmenopausal women with hormone-receptor-positive advanced breast cancer as second-line therapy postdisease progression after aromatase inhibitors or tamoxifen.
|
28717399 |
2017 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Everolimus significantly improves progression-free survival (PFS) and has been approved to use in aromatase inhibitor pretreated patients with hormone receptor positive advanced breast cancer.
|
29137418 |
2017 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
|
28968163 |
2017 |
|
Advanced breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer.
|
27269946 |
2016 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Post-menopausal women aged ≥18 years with hormone receptor-positive, human epidermal growth factor-receptor-2-negative advanced breast cancer (ABC) recurring/progressing during/after prior non-steroidal aromatase inhibitors were enrolled.
|
27358383 |
2016 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Third-generation aromatase inhibitors (letrozole, anastrozole) have shown superior efficacy in early and advanced breast cancer compared with tamoxifen.
|
22738819 |
2012 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aromatase inhibitors (AIs) are an important class of endocrine drugs used in the treatment of early and advanced breast cancer in postmenopausal women.
|
22515612 |
2012 |
|
Advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aromatase inhibitors letrozole and anastrozole have been approvedrecently as first-line treatment options for hormone-dependent advanced breast cancer.
|
12114443 |
2002 |
|
Advanced breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular variants of the CYP 19 gene are associated with an increased risk for developing breast cancer, advanced breast cancer stages, and tumor aromatase production.
|
12020974 |
2002 |